CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy

Seung Tae Kim, Kyong Hwa Park, Jun Suk Kim, Sang Won Shin, Yeul Hong Kim

Cancer Research and Treatment. 2013;45(1):55-62. Published online 2013 March 31 DOI: https://doi.org/10.4143/crt.2013.45.1.55

Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy

Seung Tae Kim, Kyong Hwa Park, Jun Suk Kim, Sang Won Shin, Yeul Hong Kim

Cancer Research and Treatment. 2013;45(1):55-62

Link1

Link2

To Give or Not to Give Anti–Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies to Patients With KRAS G13D Mutation in Advanced Colorectal Cancer

Richard Kim, Timothy Kubal

Clinical Colorectal Cancer. 2012;11(2):85-87

Link1 Link2

Colorectal carcinomas, KRAS p.G13D mutant allele-specific imbalance, and anti-epidermal growth factor receptor therapy

Douglas J. Hartman, Simion I. Chiosea

Cancer. 2013;119(24):4366-4366

Link1 Link2

MC13-0021 Impact of post-protocol anti-epidermal growth factor receptor therapy on survival in wild-type KRAS/NRAS metastatic colorectal cancer: Data from the PRIME study

M. Peeters, J.Y. Douillard, S. Siena, T. Price, J. Tabernero, R. Sidhu, S. Braun, A. Rong

European Journal of Cancer. 2013;49:S17

Link1 Link2

Effect of Post-Protocol Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal AntiBody (MAB) Therapy on Survival Outcomes in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Treated with Panitumumab (PMAB) Plus Chemotherapy

J.-Y. Douillard, M. Peeters, A. Rong, S. Siena, S. Braun, R. Sidhu, T. Price

Annals of Oncology. 2012;23:ix194-ix195

Link1 Link2

Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysis

Albert Y. Lin, Nicholas S. Buckley, An-Ting T. Lu, Natalia B. Kouzminova, Shelley R. Salpeter

Clinical Colorectal Cancer. 2011;10(1):63-69

Link1 Link2

Reply to colorectal carcinomas, KRAS p.G13D mutant allele-specific imbalance, and anti-epidermal growth factor receptor therapy

Janghee Woo, John C. Leighton

Cancer. 2013;119(24):4366-4367

Link1 Link2

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients

Monic Roengvoraphoj, Gregory J. Tsongalis, Konstantin H. Dragnev, James R. Rigas

Cancer Treatment Reviews. 2013;39(8):839-850

Link1 Link2

Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?

Ender Dogan, Sedat T Firat, Ramazan Cosar, Oktay Bozkurt, Mevlude Inanc, Metin Ozkan

Journal of Oncology Pharmacy Practice. 2019;26(4):781-786

Link1 Link2 Link3

Clinical and Economic Aspects of <i>KRAS </i>Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

Robert Königsberg, Wolfgang Hulla, Martin Klimpfinger, Angelika Reiner-Concin, Tanja Steininger, Wilfried Büchler, Robert Terkola, Christian Dittrich

Oncology. 2011;81(5-6):359-364

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.